Drug Trial Radar · NCT07505303
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
151
Actual
Start
Mar 23, 2026
Primary completion
Oct 15, 2026
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- EccogeneIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Conditions
- Adult Obesity
- Weight Management
Interventions
ECC4703Drug
orally QD
PlaceboDrug
orally QD
SemaglutideDrug
SC once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in Body Weight from Baseline (Week 9) to Week 20Time frame: Baseline (Week 9) to Week 20
- Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20Time frame: Baseline (Week 9) to Week 20
- Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisTime frame: Baseline (Week 9) to Week 20
- Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisTime frame: Baseline (Week 9) to Week 20
- Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFFTime frame: Baseline (Week 9) to Week 20
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Central Research Associates - Flourish - PPDS
Birmingham, Alabama
Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS
Anaheim, California
Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS
Los Alamitos, California
AES - DRS - Optimal Research Florida - Melbourne
Melbourne, Florida
ForCare Clinical Research - CenExel FCR - PPDS
Tampa, Florida
Atlanta Center for Medical Research - CenExel ACMR - PPDS
Atlanta, Georgia
iResearch Atlanta - CenExel - PPDS
Decatur, Georgia
AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis
Richfield, Minnesota
Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS
Omaha, Nebraska
Velocity Clinical Research - Durham - PPDS
Durham, North Carolina
Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS
Cincinnati, Ohio
Velocity Clinical Research - Providence - PPDS
East Greenwich, Rhode Island
Velocity Clinical Research - Dallas - PPDS
Dallas, Texas
AES - DRS - Synexus Clinical Research US, Inc. - San Antonio
San Antonio, Texas
Flourish Research - San Antonio - PPDS
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.